RFX6
DNA-binding protein RFX6
Also known as: dJ955L16.1, MGC33442, RFX6_HUMAN, RFXDC1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8HWS3
- Gene
- RFX6
- Ensembl
- ENSG00000185002
- Chromosome
- 6
- Canonical length
- 928 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
OverviewNCBI Gene
The nuclear protein encoded by this gene is a member of the regulatory factor X (RFX) family of transcription factors. Studies in mice suggest that this gene is specifically required for the differentiation of islet cells for the production of insulin, but not for the differentiation of pancreatic polypeptide-producing cells. It regulates the transcription factors involved in beta-cell maturation and function, thus, restricting the expression of the beta-cell differentiation and specification genes. Mutations in this gene are associated with Mitchell-Riley syndrome, which is characterized by neonatal diabetes with pancreatic hypoplasia, duodenal and jejunal atresia, and gall bladder agenesis.[provided by RefSeq, Sep 2010]
Canonical amino-acid sequenceUniProt
928 residues, UniProt reviewed canonical sequence.
>Q8HWS3|RFX6
1 MAKVPELEDT FLQAQPAPQL SPGIQEDCCV QLLGKGLLVY PEETVYLAAE GQPGGEQGGG
61 EKGEDPELPG AVKSEMHLNN GNFSSEEEDA DNHDSKTKAA DQYLSQKKTI TQIVKDKKKQ
121 TQLTLQWLEE NYIVCEGVCL PRCILYAHYL DFCRKEKLEP ACAATFGKTI RQKFPLLTTR
181 RLGTRGHSKY HYYGIGIKES SAYYHSVYSG KGLTRFSGSK LKNEGGFTRK YSLSSKTGTL
241 LPEFPSAQHL VYQGCISKDK VDTLIMMYKT HCQCILDNAI NGNFEEIQHF LLHFWQGMPD
301 HLLPLLENPV IIDIFCVCDS ILYKVLTDVL IPATMQEMPE SLLADIRNFA KNWEQWVVSS
361 LENLPEALTD KKIPIVRRFV SSLKRQTSFL HLAQIARPAL FDQHVVNSMV SDIERVDLNS
421 IGSQALLTIS GSTDTESGIY TEHDSITVFQ ELKDLLKKNA TVEAFIEWLD TVVEQRVIKT
481 SKQNGRSLKK RAQDFLLKWS FFGARVMHNL TLNNASSFGS FHLIRMLLDE YILLAMETQF
541 NNDKEQELQN LLDKYMKNSD ASKAAFTASP SSCFLANRNK GSMVSSDAVK NESHVETTYL
601 PLPSSQPGGL GPALHQFPAG NTDNMPLTGQ MELSQIAGHL MTPPISPAMA SRGSVINQGP
661 MAGRPPSVGP VLSAPSHCST YPEPIYPTLP QANHDFYSTS SNYQTVFRAQ PHSTSGLYPH
721 HTEHGRCMAW TEQQLSRDFF SGSCAGSPYN SRPPSSYGPS LQAQDSHNMQ FLNTGSFNFL
781 SNTGAASCQG ATLPPNSPNG YYGSNINYPE SHRLGSMVNQ HVSVISSIRS LPPYSDIHDP
841 LNILDDSGRK QTSSFYTDTS SPVACRTPVL ASSLQTPIPS SSSQCMYGTS NQYPAQETLD
901 SHGTSSREMV SSLPPINTVF MGTAAGGTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RFX6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.5
- Highest tissue expression
- 6.1 nTPM
Expression across tissuesHPA
Tissue
- stomach: 6.1 nTPM
- adrenal gland: 4.3 nTPM
- pancreas: 2.2 nTPM
- duodenum: 2.1 nTPM
- rectum: 1.2 nTPM
- small intestine: 1.2 nTPM
Single-cell type
- pancreatic islet cells: 307 nCPM
- neuroendocrine cells: 262 nCPM
- adrenal medulla cells: 170 nCPM
- salivary ionocytes: 30 nCPM
- cytotrophoblasts: 18 nCPM
- syncytiotrophoblasts: 4.9 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RFX6.
Disease | AllUniProt
Conditions RFX6 is implicated in, by any mechanism.
- Mitchell-Riley syndrome (MTCHRS) MIM:615710
Disease | GeneticClinVar
39 pathogenic / likely-pathogenic of 390 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hypoplastic pancreas-intestinal atresia-hypoplastic gallbalder syndrome
- RFX6-related disorder
- Diabetes mellitus
- Maturity-onset diabetes of the young
- Monogenic diabetes
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.47
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.2
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- endocrine pancreas development
- glucose homeostasis
- pancreatic A cell differentiation
- pancreatic D cell differentiation
- positive regulation of DNA-templated transcription
- positive regulation of insulin secretion involved in cellular response to glucose stimulus
- positive regulation of transcription by RNA polymerase II
- regulation of insulin secretion
- regulation of transcription by RNA polymerase II
- type B pancreatic cell differentiation
- pancreatic epsilon cell differentiation
Molecular functions
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- transcription cis-regulatory region binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RFX6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RFX6 as an antibody target. Whether an autoantibody or antibody against RFX6 could matter depends on whether native RFX6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RFX6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RFX6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...